Details for Patent: 9,737,491
✉ Email this page to a colleague
Which drugs does patent 9,737,491 protect, and when does it expire?
Patent 9,737,491 protects EYSUVIS and INVELTYS and is included in two NDAs.
This patent has nineteen patent family members in seven countries.
Summary for Patent: 9,737,491
| Title: | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| Abstract: | Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier. |
| Inventor(s): | Popov; Alexey (Waltham, MA), Enlow; Elizabeth M. (Waltham, MA), Bourassa; James (Somerville, MA), Gardner; Colin R. (Concord, MA), Chen; Hongming (Belmont, MA), Ensign; Laura M. (Towson, MD), Lai; Samuel K. (Carrboro, NC), Yu; Tao (Baltimore, MD), Hanes; Justin (Baltimore, MD), Yang; Ming (Towson, MD) |
| Assignee: | The Johns Hopkins University (Baltimore, MD) |
| Application Number: | 15/354,704 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 9,737,491
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER | ⤷ Try a Trial | ||||
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,737,491
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013256130 | ⤷ Try a Trial | |||
| Australia | 2018201772 | ⤷ Try a Trial | |||
| Australia | 2020203213 | ⤷ Try a Trial | |||
| Canada | 2871778 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
